The changing role of H2-receptor antagonists in acid-related diseases

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue SUPPL. 1, 1996, Pages

  Lamers, Cornelis B H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Duodenal ulcer; Gastric ulcer; Gastroesophageal reflux disease; H2 receptor antagonist; Helicobacter pylori; Proton pump inhibitor

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; PROTON PUMP INHIBITOR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; OMEPRAZOLE; PANTOPRAZOLE; RANITIDINE; SULFOXIDE;

ANTIMICROBIAL THERAPY; ARTICLE; DOSE TIME EFFECT RELATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION; CLINICAL TRIAL; DRUG ANTAGONISM; DYSPEPSIA; REVIEW;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS; DYSPEPSIA; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE H2 ANTAGONISTS; HUMANS; OMEPRAZOLE; PEPTIC ULCER; RANITIDINE; SULFOXIDES;

EID: 0029823295     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199610001-00002     Document Type: Article

References (39)

1. NIH Consensus development Panel: Helicobacter pylori in peptic ulcer disease. JAMA 1994, 272:65-69.
2. Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, et al.: Pharmacological aspects of acid secretion. Dig Dis Sci 1995, 2 (suppl 2):3S-23S.
3. Londong W: Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994, 8 (suppl 1):39-46.
4. Hurlimann S, Abbuhl B, Inauen W, Halter F: Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994, 8:93-201.
5. Dixon JS: Helicobacter pylori eradication: unravelling the facts. Scand J Gastroenterol 1995, 30 (suppl 212):48-62.
6. Sung JJY, Chung SCS, Ling TKW, Yung MY, Leung VKS, Ng EKW, et al.: Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995, 332:139-142.
7. De Bruigne JW, Lamers CBHW, Dekkers CPM: Omeprazole induces faster healing and pain relief than cimetidine in duodenal ulcer patients. J Clin Nutr Gastroenterol 1993, 8:1-6.
8. Bader JP, Delchier JC: Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994, 8 (suppl 1):47-52.
9. Hotz J, Plein K, Schönekäs H, Rose K: Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Scand J Gastroenterol 1995, 30:11-15.
10. Morgan DG, Burget DW, Howden CW, Jacobson K, Wong D, Hewak J, et al.: Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis [abstract]. Gastroenterology 1993, 104:A150.
11. Howden CW, Burget DW, Wilkinson J, Hunt RH: A comparison of different drug classes with respect to rapidity of healing of gastric ulcer (GU) [abstract]. Gastroenterology 1993, 104:A105.
12. 2-receptor antagonists. Aliment Pharmacol Ther 1987, 1:31-38.
13. Brunner G, Harke U: Long term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994, 8 (suppl 1):59-64.
14. Adamek RJ, Szymanski C, Pfaffenbach B, Opferkuch W, Ricken D, Wegener M: Effect of a short course of triple therapy with pantoprazole, clarithromycin and metronidazole on healing of Helicobacter pylori infection [in German]. Dtsch Med Wochenschr 1995, 120:358-360.
15. Labenz J, Peitz U, Tillenburg B, Becker T, Borsch G, Stolte M: Effect of a short course of triple therapy with pantoprazole, clarithromycin and metronidazole on the eradication of Helicobater pylori infection [in German]. Leben Magen Darm 1995, 25:122-127.
16. Penston JG, Wormgsley KG: Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmacol Ther 1992, 6:629-645.
17. Penston JG, Wormsley KG: Long-term maintenance treatment of gastric ulcers with ranitidine. Aliment Pharmacol Ther 1990, 4:339-355.
18. Jensen DM, Cheng S, Kovacs TOG, Randall G, Jensen ME, Reedy T, et al.: A controlled study of ranitidine for the prevention of recurrent haemorrhage from duodenal ulcer. N Engl J Med 1994, 330:382-386.
19. Penston JG: Helicobacter pylori eradication; understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994, 8:369-389.
20. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995, 9 (suppl 1):9-14.
21. Johnson NJ, Boyd EJS, Mills JG, Wood JR: Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989, 3:259-266.
22. Mckenna CJ, Mills JG, Goodwin C, Wood JR: Combination of ranitidine and cisapride in the treatment of reflux oesophagitis. Eur J Gastroenterol Hepatol 1995, 7:817-822.
23. Bell NJV, Hunt RH: Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992, 33:118-124.
24. Koop H, Schepp W, Dammann HG, Schneider A, Lühmann R, Classen M: Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. J Clin Gastroenterol 1995, 20:192-195.
25. Chiba N, de Gara CJ, Burget DW, Wilkinson J, Hunt J: Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis [abstract]. Gastroenterology 1993, 104: A53.
26. Klinkenberg-Knol EC, Festen HP, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al.: Long-term treatment with omeprazole for refractory reflux esopnagitis: efficacy and safety. Ann Intern Med 1994, 121:161-167.
27. 2-receptor antagonists: how will they affect the treatment of acid-related diseases? Drugs 1994, 47:1-11.
28. Colin-Jones D: Management of dyspepsia: report of a working party. Lancef 1988, i:576-579.
29. Lamers CBHW: Functional dyspepsia: where do we stand? Scand J Gastroenterol 1993, 28 (suppl 200):96-97.
30. Saunders JHB, Oliver RJ, Higson DL: Dyspepsia: incidence of non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ 1986, 292:665-668.
31. Dobrilla G, Comberlato M, Steele A, Vallaperta P: Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989, 11:169-177.
32. Smallwood RA, Berlin RG, Castagnoli N, Festen HPM, Hawkey CJ, Lam SK, et al.: Safety of acid-suppressing drugs. Dig Dis Sci 1995, 40 (suppl 2):63S-80S.
33. Wormsley KG: Safely profile of ranitidine. Drugs 1993, 46:976-985.
34. Arnold R: Safety of proton pump inhibitors: an overview. Aliment Pharmacol Ther 1994, 8 (suppl 1):65-70.
35. Freston JW: On-demand treatment for duodenal ulcers: has its time come? Am J Gastroenterol 1990, 85:241-242.
36. Thorat VK, Misra SP, Anand BS: Conventional versus on-demand therapy for duodenal ulcer: results of a controlled therapeutic trial. Am J Gastroenterol 1990, 85:243-248.
37. 2-antagonist: symptomatic self-care compared with maintenance treatment. Aliment Pharmacol Ther 1992, 6:315-325.
38. 2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacol Toxicol 1991, 69:253-258.
39. Petersen H, Kristensen P, Johannessen T, Kleveland PM, Dybdahl JH: The natural course of peptic ulcer disease and its predictors. Scand J Gastroenterol 1995, 30:17-24.